SFM
CALT

Sphera Funds Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Sphera Funds Management’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,863
Closed -$217K – 110
2023
Q3 		$217K Buy
+11,863
New +$205K 0.04% 82

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sphera Funds Management's CALT Position: Q4 2023 in Review

Sphera Funds Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q4 2023, closing a stake of 11,863 shares — an estimated $217K sold.

Sphera Funds Management first reported a position in CALT in Q3 2023 and held it in 1 quarter. The position peaked at $217K in Q3 2023. 21 funds tracked by Wall St. Rank hold CALT as of Q4 2023.

  • Sphera Funds Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q4 2023 after selling out during the quarter.
  • Sphera Funds Management sold 11,863 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2023, an estimated $217K.
  • Sphera Funds Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q3 2023 and held it in 1 quarter.
  • Sphera Funds Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $217K in Q3 2023.
  • 21 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2023.

Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.